VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 715 filers reported holding VANECK VECTORS ETF TR in Q4 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,113,735 | -24.7% | 237,177 | -12.0% | 0.04% | -24.5% |
Q2 2023 | $8,117,113 | +41.9% | 269,582 | +52.4% | 0.05% | +32.4% |
Q1 2023 | $5,721,918 | +18.0% | 176,875 | +4.5% | 0.04% | +5.7% |
Q4 2022 | $4,849,661 | +66.5% | 169,214 | +40.1% | 0.04% | +52.2% |
Q3 2022 | $2,913,000 | -11.0% | 120,761 | +1.0% | 0.02% | -11.5% |
Q2 2022 | $3,273,000 | -41.3% | 119,554 | -17.8% | 0.03% | -31.6% |
Q1 2022 | $5,578,000 | +96.5% | 145,450 | +64.2% | 0.04% | +90.0% |
Q4 2021 | $2,838,000 | +4.8% | 88,603 | -3.6% | 0.02% | -9.1% |
Q3 2021 | $2,709,000 | -12.4% | 91,940 | -1.7% | 0.02% | -18.5% |
Q2 2021 | $3,093,000 | +521.1% | 93,560 | +510.1% | 0.03% | +440.0% |
Q1 2021 | $498,000 | -14.0% | 15,336 | -4.5% | 0.01% | -28.6% |
Q4 2020 | $579,000 | -41.3% | 16,062 | -36.2% | 0.01% | -50.0% |
Q3 2020 | $986,000 | -39.5% | 25,174 | -43.3% | 0.01% | -44.0% |
Q2 2020 | $1,629,000 | +581.6% | 44,398 | +375.5% | 0.02% | +257.1% |
Q2 2019 | $239,000 | – | 9,337 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $19,873,035 | 80.92% |
New Harbor Financial Group, LLC | 1,680,752 | $45,229,033 | 14.96% |
TORQ CAPITAL MANAGEMENT (HK) Ltd | 139,000 | $3,740,490 | 9.95% |
Vanderbilt University | 1,360,540 | $36,612,131 | 9.45% |
Eschler Asset Management LLP | 300,000 | $8,073,000 | 9.42% |
New Harbor Financial Group, LLC | 1,027,300 | $27,644,643 | 9.15% |
Guild Investment Management, Inc. | 139,333 | $3,749,454 | 6.28% |
Monaco Asset Management SAM | 750,000 | $20,182,500 | 5.98% |
STRATEGIC INVESTMENT MANAGEMENT, LLC | 132,460 | $3,867,832 | 4.74% |
PCG Wealth Advisors, LLC | 264,614 | $7,120,782 | 4.67% |